Done sou Salè H1B

Akèy › Anplwayè › Experic LLC

Experic LLC: Salè H-1B ak pajon

Experic LLC depoze 5 aplikasyon kondisyon travay pou visa H-1B ak visa ki gen rapò nan ane fiskal 2023–2026; sètifye: 4. Medyèn salè yo ofri a: $130,356.

Demann (LCA)5
Certifye4
Adrès anplwayèCranbury, NJ
Anplwayè H-1B depannNon
Salè medyan ofri$130,356
Mwatye salè yo$122,756–$141,932
10yèm–90yèm pousantaj$118,491–$153,356

Èske Experic LLC pajone visa H-1B?

Experic LLC depoze 5 aplikasyon kondisyon travay nan ane fiskal 2023–2026, dènye a soumèt sou Apr 4, 2026. Yon LCA se premye etap yon demann H-1B, konsa anplwayè a pajone oswa prepare pou pajone travayè H-1B; li pa garanti pajon pou okenn travay espesifik. Tcheke lis travay pwòp anplwayè a.

Salè pa tit travay

Tit travayLCASalè medyan
Engineer/Scientist3$130,356
Associate Director, Pharmaceutical Development1$160,971
Senior Scientist1$115,648

Aplikasyon pa ane fiskal

Ane fiskalLCASalè medyan
FY20254$125,126
FY20261$135,586

Nivo salè prevanlan

Depatman Travay la etabli kat nivo salè prevanlan pou chak okipasyon ak zòn, soti nan Nivo I (antre) rive nan Nivo IV (plen kompetans). Anplwayè a chwazi nivo ki koresponn ak kondisyon travay la.

Kote travay yo ye

Okipasyon

Dènye aplikasyon yo

Tit travaySalè bazKoteSoumètDat kòmansmanEstati
Engineer/Scientist$135,586
Nivo III
Cranbury, NJApr 4, 2026Oct 1, 2026Certifye
Engineer/Scientist$125,126
Nivo III
Cranbury, NJJun 23, 2025Aug 8, 2025Certifye
Engineer/Scientist$98,135–$125,126
Nivo III
Cranbury, NJJun 17, 2025Aug 8, 2025Retire
Associate Director, Pharmaceutical Development$160,971–$165,641
Nivo II
Cranbury, NJFeb 19, 2025Aug 8, 2025Certifye
Senior Scientist$115,648–$125,000
Nivo IV
Cranbury, NJFeb 13, 2025Mar 31, 2025Certifye

Salè yo se fen ki pi ba nan salè yo ofri sou chak aplikasyon, konvèti nan yon montan anyèl; estatistik yo itilize sèlman aplikasyon tan plen sètifye. Yon LCA pa yon apwobasyon visa epi yon sèl LCA ka kouvri plizyè pozisyon. Sous: Depatman Travay Etazini, Done Divulgasyon LCA OFLC, ane fiskal 2023–2026 (dènye desizyon Jun 30, 2026).